We are preparing the requested document. Please wait, this may take a while...!
|Antigen||Tumor Necrosis Factor Receptor Superfamily, Member 10b (TNFRSF10B) Antibodies|
|Epitope||AA 233-440 Alternatives|
|Reactivity||Human, Mouse (Murine), Rat (Rattus) Alternatives|
|Conjugate||This TNFRSF10B antibody is un-conjugated Alternatives|
Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)
|Supplier||Log in to see|
Product Details anti-TNFRSF10B AntibodyTarget Details TNFRSF10B Application Details Handling Images
|Purpose||Rabbit IgG polyclonal antibody for Tumor necrosis factor receptor superfamily member 10B(TNFRSF10B) detection. Tested with WB, IHC-P in Human,Mouse,Rat.|
|Cross-Reactivity (Details)||No cross reactivity with other proteins.|
Rabbit IgG polyclonal antibody for Tumor necrosis factor receptor superfamily member 10B(TNFRSF10B) detection. Tested with WB, IHC-P in Human,Mouse,Rat.
Gene Name: tumor necrosis factor receptor superfamily, member 10b
Protein Name: Tumor necrosis factor receptor superfamily member 10B
|Purification||Immunogen affinity purified.|
|Immunogen||E.coli-derived human DR5 recombinant protein (Position: K233-S440). Human DR5 shares 48.4% amino acid (aa) sequence identity with mouse DR5.|
|Plasmids, Primers & others|
Target Details TNFRSF10BProduct Details anti-TNFRSF10B Antibody Application Details Handling Images back to top
TNFRSF10B(Tumor necrosis factor receptor superfamily, member 10b) is a human gene. It is also known as DR5, CD262, KILLER, TRICK2, TRICKB, ZTNFR9, TRAILR2, TRICK2A, TRICK2B, TRAIL-R2, KILLER/DR5. The protein encoded by this gene is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces apoptosis signal. Mice have a homologous gene, tnfrsf10b that has been essential in the elucidation of the function of this gene in humans. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein.By analysis of radiation hybrid panels, this gene is mapped to chromosome 8p22-p21. Northern blot analysis indicated that TRAILR2 was expressed as a 4.4-kb mRNA in all tissues tested, with the highest levels of expression in peripheral blood lymphocytes, spleen, and ovary.
Synonyms: CD262 antigen | Cytotoxic TRAIL receptor 2 | DR5 | Dr5 | Killer | KILLER | O14763 | TNFRSF10B | TR10B | trail r2 | trailr 2 | TRAILR2 | TRAIL-R2 | TRICK2 | TRICK2A | TRICK2B
|Pathways||p53 Signaling, Apoptosis, Positive Regulation of Endopeptidase Activity|
Application DetailsProduct Details anti-TNFRSF10B Antibody Target Details TNFRSF10B Handling Images back to top
WB: Concentration: 0.1-0.5 μg/mL, Tested Species: Human, Mouse, Rat
IHC-P: Concentration: 0.5-1 μg/mL, Tested Species: Human, Mouse, Rat, Epitope Retrieval by Heat: Boiling the paraffin sections in 10 mM citrate buffer, pH 6.0, for 20 mins is required for the staining of formalin/paraffin sections.
Notes: Tested Species: Species with positive results. Other applications have not been tested. Optimal dilutions should be determined by end users.
Antibody can be supported by chemiluminescence kit ABIN921124 in WB, supported by ABIN921231 in IHC(P).
|Restrictions||For Research Use only|
HandlingProduct Details anti-TNFRSF10B Antibody Target Details TNFRSF10B Application Details Images back to top
|Reconstitution||Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.|
|Buffer||Each vial contains 5 mg BSA, 0.9 mg NaCl, 0.2 mg Na2HPO4, 0.05 mg Sodium azide.|
|Precaution of Use||This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.|
|Storage||4 °C,-20 °C|
At -20°C for one year. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20 °C for a longer time. Avoid repeated freezing and thawing.
ImagesProduct Details anti-TNFRSF10B Antibody Target Details TNFRSF10B Application Details Handling back to top